O	0	6	Effect
O	7	9	of
B-intervention	10	18	decision
I-intervention	19	22	aid
O	23	26	for
O	27	33	breast
O	34	40	cancer
O	41	51	prevention
O	52	54	on
O	55	65	decisional
O	66	74	conflict
O	75	77	in
O	78	83	women
O	84	88	with
O	89	90	a
O	91	96	BRCA1
O	97	99	or
O	100	105	BRCA2
O	106	114	mutation
O	114	115	:
O	116	117	a
O	118	127	multisite
O	127	128	,
O	129	139	randomized
O	139	140	,
O	141	151	controlled
O	152	157	trial
O	157	158	.

O	159	164	Women
O	165	169	with
O	170	171	a
O	172	177	BRCA1
O	178	180	or
O	181	186	BRCA2
O	187	195	mutation
O	196	199	are
O	200	202	at
O	203	207	high
O	208	212	risk
O	213	216	for
O	217	223	breast
O	224	230	cancer
O	231	234	and
O	235	239	must
O	240	244	make
O	245	254	important
O	255	264	decisions
O	265	270	about
O	271	277	breast
O	278	284	cancer
O	285	295	prevention
O	296	299	and
O	300	309	screening
O	309	310	.

O	311	313	In
O	314	317	the
O	318	325	current
O	326	331	study
O	331	332	,
O	333	335	we
O	336	342	report
O	343	344	a
O	345	354	multisite
O	354	355	,
O	356	366	randomized
O	366	367	,
O	368	378	controlled
O	379	384	trial
O	385	395	evaluating
O	396	399	the
O	400	413	effectiveness
O	414	416	of
O	417	418	a
O	419	427	decision
O	428	431	aid
O	432	435	for
O	436	442	breast
O	443	449	cancer
O	450	460	prevention
O	461	463	in
B-eligibility	464	469	women
I-eligibility	470	474	with
I-eligibility	475	476	a
I-eligibility	477	481	BRCA
I-eligibility	482	490	mutation
I-eligibility	491	495	with
I-eligibility	496	498	no
I-eligibility	499	507	previous
I-eligibility	508	517	diagnosis
I-eligibility	518	520	of
I-eligibility	521	527	cancer
O	527	528	.

O	529	535	Within
O	536	537	1
O	538	543	month
O	544	546	of
O	547	556	receiving
O	557	558	a
O	559	567	positive
O	568	572	BRCA
O	573	579	result
O	579	580	,
O	581	586	women
O	587	591	were
O	592	602	randomized
O	603	605	to
O	606	613	receive
O	614	620	either
B-control	621	626	usual
I-control	627	631	care
I-control	632	633	(
I-control	633	640	control
I-control	641	646	group
I-control	646	647	)
O	648	650	or
O	651	659	decision
O	660	663	aid
O	664	665	(
O	665	677	intervention
O	678	683	group
O	683	684	)
O	684	685	.

O	686	698	Participants
O	699	703	were
O	704	712	followed
O	713	715	at
O	716	717	3
O	717	718	,
O	719	720	6
O	720	721	,
O	722	725	and
O	726	728	12
O	729	735	months
O	735	736	;
O	737	741	were
O	742	747	asked
O	748	753	about
O	754	764	preventive
O	765	773	measures
O	773	774	;
O	775	778	and
O	779	788	completed
O	789	801	standardized
O	802	816	questionnaires
O	817	826	assessing
O	827	835	decision
O	836	842	making
O	843	846	and
O	847	859	psychosocial
O	860	871	functioning
O	871	872	.

B-total-participants	873	876	One
I-total-participants	877	884	hundred
I-total-participants	885	890	fifty
O	891	896	women
O	897	901	were
O	902	912	randomized
O	912	913	.

B-outcome	914	918	Mean
I-outcome	919	925	cancer
I-outcome	925	926	-
I-outcome	926	933	related
I-outcome	934	942	distress
I-outcome	943	949	scores
O	950	954	were
O	955	968	significantly
O	969	974	lower
O	975	977	in
O	978	981	the
O	982	994	intervention
O	995	1000	group
O	1001	1009	compared
O	1010	1014	with
O	1015	1018	the
O	1019	1026	control
O	1027	1032	group
B-outcome	1033	1035	at
I-outcome	1036	1037	6
I-outcome	1038	1044	months
O	1045	1046	(
O	1046	1047	P
O	1048	1049	=
O	1050	1051	0
O	1051	1052	.
O	1052	1054	01
O	1054	1055	)
O	1056	1059	and
B-outcome	1060	1062	at
I-outcome	1063	1065	12
I-outcome	1066	1072	months
O	1073	1090	postrandomization
O	1091	1092	(
O	1092	1093	P
O	1094	1095	=
O	1096	1097	0
O	1097	1098	.
O	1098	1100	05
O	1100	1101	)
O	1101	1102	.

B-outcome	1103	1113	Decisional
I-outcome	1114	1122	conflict
I-outcome	1123	1129	scores
I-outcome	1130	1138	declined
I-outcome	1139	1143	over
I-outcome	1144	1148	time
O	1149	1152	for
O	1153	1157	both
O	1158	1164	groups
O	1165	1168	and
O	1169	1171	at
O	1172	1174	no
O	1175	1179	time
O	1180	1184	were
O	1185	1190	there
O	1191	1202	statistical
O	1203	1214	differences
O	1215	1222	between
O	1223	1226	the
O	1227	1230	two
O	1231	1237	groups
O	1237	1238	.

O	1239	1242	The
O	1243	1251	decision
O	1252	1255	aid
O	1256	1259	for
O	1260	1266	breast
O	1267	1273	cancer
O	1274	1284	prevention
O	1285	1287	in
O	1288	1293	women
O	1294	1298	with
O	1299	1300	a
O	1301	1306	BRCA1
O	1307	1309	or
O	1310	1315	BRCA2
O	1316	1324	mutation
O	1325	1327	is
O	1328	1337	effective
O	1338	1340	in
O	1341	1354	significantly
O	1355	1365	decreasing
O	1366	1372	cancer
O	1372	1373	-
O	1373	1380	related
O	1381	1389	distress
O	1390	1396	within
O	1397	1400	the
O	1401	1405	year
O	1406	1415	following
O	1416	1423	receipt
O	1424	1426	of
O	1427	1435	positive
O	1436	1443	genetic
O	1444	1448	test
O	1449	1456	results
O	1456	1457	.
O	1457	1462	Genet
O	1463	1466	Med
O	1467	1469	19
O	1470	1471	3
O	1471	1472	,
O	1473	1476	330
O	1476	1477	-
O	1477	1480	336
O	1480	1481	.
